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BRIEF REVIEW
Orchestration of Primary Hemostasis by Platelet 
and Endothelial Lysosome-Related Organelles
Ellie Karampini, Ruben Bierings, Jan Voorberg
ABSTRACT: Megakaryocyte-derived platelets and endothelial cells store their hemostatic cargo in α- and δ-granules and Weibel-
Palade bodies, respectively. These storage granules belong to the lysosome-related organelles (LROs), a heterogeneous 
group of organelles that are rapidly released following agonist-induced triggering of intracellular signaling pathways. Following 
vascular injury, endothelial Weibel-Palade bodies release their content into the vascular lumen and promote the formation 
of long VWF (von Willebrand factor) strings that form an adhesive platform for platelets. Binding to VWF strings as well as 
exposed subendothelial collagen activates platelets resulting in the release of α- and δ-granules, which are crucial events in 
formation of a primary hemostatic plug. Biogenesis and secretion of these LROs are pivotal for the maintenance of proper 
hemostasis. Several bleeding disorders have been linked to abnormal generation of LROs in megakaryocytes and endothelial 
cells. Recent reviews have emphasized common pathways in the biogenesis and biological properties of LROs, focusing mainly 
on melanosomes. Despite many similarities, LROs in platelet and endothelial cells clearly possess distinct properties that allow 
them to provide a highly coordinated and synergistic contribution to primary hemostasis by sequentially releasing hemostatic 
cargo. In this brief review, we discuss in depth the known regulators of α- and δ-granules in megakaryocytes/platelets and 
Weibel-Palade bodies in endothelial cells, starting from transcription factors that have been associated with granule formation 
to protein complexes that promote granule maturation. In addition, we provide a detailed view on the interplay between platelet 
and endothelial LROs in controlling hemostasis as well as their dysfunction in LRO related bleeding disorders.
VISUAL OVERVIEW: An online visual overview is available for this article.
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Lysosome-related organelles (LROs) are specialized storage compartments that include melanosomes in skin and eye melanocytes, lytic granules of cytotoxic 
T cells and natural killer cells, alpha (α) and dense (δ) 
granules in platelets, as well as Weibel-Palade bodies 
(WPB) in endothelial cells.1 Originally evolving from lyso-
somes, they have critically adapted to a highly specialized 
physiological role in the storage, clustering and regulated 
on demand release of bioactive components.1 In line with 
their evolutionary origin LROs, or as recently proposed 
endo-lysome related organelles,1 share common fea-
tures with endosomes.2 In this review, we focus on the 
biogenesis, morphological features, and physiological 
role of LROs present in platelets and endothelial cells 
which are released in a coordinated fashion during pri-
mary hemostasis. Megakaryocytes and platelets contain 
2 types of LROs, the α-, and δ-granules, whereas endo-
thelial cells contain only one, the WPBs. Each type of 
LRO can be considered as the adaptation of the cell’s 
endosomes into functional secretory organelles that 
have evolved to specific physiological needs related to 
on demand cargo delivery.1 Although LROs are similar 
enough to be placed in the same category, they differ 
in their stored cargoes, which is highly cell specific. In 
megakaryocytes, α-granules contain hemostatic proteins 
like VWF (von Willebrand factor) and Fbg (fibrinogen), 
whereas δ-granules store small molecules like ATP, Ca2+ 
and serotonin as well as the tetraspanin CD63.3 Simi-
lar to α-granules, WPBs primarily store VWF, along with 
a diverse cocktail of proinflammatory and angiogenic 
proteins, but also CD63.4 Because of their absence or 
dysfunction in specific bleeding disorders, both platelet 
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granules and WPBs have been positioned as master 
orchestrators of primary hemostasis.
At the site of vascular damage, endothelial cell activa-
tion drives the bulk expulsion of highly condensed VWF 
from WPBs and their conversion into adhesive strings, 
that serve as a landing platform for platelets.5 Platelets are 
arrested from the circulation by GPIb-V-IX/VWF interac-
tion, which is the predominant receptor-ligand interaction 
supporting platelet recruitment (Figure 1A).6,7 Subsequently, 
adhered platelets interact with exposed subendothelial 
collagen which initiates an intracellular cascade leading 
to platelet activation (Figure 1B), which, in turn, results in 
the α- and δ-granules release and their respective cargoes 
(Figure 1C).9 In more detail, ADP released from δ-granules 
binds to the P2Y12 receptor which strongly potentiates 
collagen and thromboxane A2–mediated platelet activation, 
shape changes and aggregation.10,11 In addition, polyphos-
phate, whose trafficking mechanisms to δ-granules are still 
unclear, is released and may promote secondary hemosta-
sis by accelerating the generation of FXIa by thrombin.12 
Release of stored Fbg and VWF from α-granules during 
platelet activation is likely to contribute to cross-linking of 
the activation-dependent open conformation of integrin 
αIIbβ3 (glycoprotein IIb/IIIa), thereby promoting formation of 
a stable platelet plug.13 Apart from Fbg and VWF, multiple 
growth factors like PDGFB (platelet-derived growth factor 
subunit B) and VEGF (vascular endothelial growth factor) 
as well as chemokines like PF4 (platelet factor 4) and RAN-
TES are present in α-granules, suggesting that α-granule 
release also contributes to restoration of vascular integrity 
following injury.14,15 Besides active α- and δ-granules exocy-
tosis, platelets also release their lysosomal content16; how-
ever, this is beyond the scope of this review.
The exocytotic mechanisms of endothelial and platelet 
LROs involve a complex interplay of Rab GTPases and 
proteins of the SNARE complex, with substantial overlap 
between the endothelial and platelet exocytotic machin-
ery. However, several detailed reviews on this topic are 
already available,4,17,18 and this will, therefore, not be part of 
this review. The importance of WPB and platelet granule 
release for controlling primary hemostasis is further high-
lighted by a group of heterogeneous bleeding disorders 
due to defective biogenesis and maturation of these LROs.
In this review, we summarize new advances in LRO 
formation, highlighting the interplay and differential regu-
lation of megakaryocyte and platelet localized α- and δ-
granules and endothelial cell WPBs. We discuss in depth 
the pathways involved in the biogenesis and maturation 
of the aforementioned LROs, as well as disorders that 
are linked to defects in these pathways.
BIOGENESIS AND MATURATION OF α- 
AND δ-GRANULES IN MEGAKARYOCYTES 
AND PLATELETS
Transcription Factors in α- and δ-Granule 
Biogenesis
Several transcription factors, including RUNX1, NF-E2, 
GFI1B, and FLI1, have a crucial role in megakaryopoi-
esis and platelet formation.19,20 Their importance is illus-
trated by defects in platelet function in patients with 
genetic defects in these transcription factors.21 RUNX1 
haplodeficiency has been linked to thrombocytopenia 
and both α- and δ-granule deficiencies, while RUNX1 
knock out (KO) mice lack primary hematopoiesis.21 Two 
new studies have demonstrated that RUNX1 haplode-
ficiency decreases RAB1B and PLDN expression lev-
els which sheds light on the mechanisms for α- and 
δ-granule biogenesis, respectively.22,23 Rab1b belongs 
to the small GTPase family and facilitates vesicular 
endoplasmic reticulum (ER)-to-Golgi transport, and, in 
the case of megakaryocytes, promotes VWF intracel-
lular trafficking.22,24 Reduced RUNX1 and Rab1b levels 
were proposed to lead to defective VWF maturation and 
decreased targeting to α-granules.22 RUNX1 also con-
trols the expression of PLDN which encodes for pallidin 
Nonstandard Abbreviations and Acronyms
AMPK 5′ AMP-activated kinase
AP adaptor protein
ARM Armadillo
BEACH beige and Chediak-Higashi
CK cysteine knot
Dlg1 discs large 1
ER endoplasmic reticulum
Fbg fibrinogen
GAP GTPase-activating protein
GEF guanine nucleotide exchange factor
HPS Hermansky-Pudlak syndrome
KO knock out
LRO lysosome-related organelle
MVB multivesicular body
PF4 platelet factor 4
PI4K phosphatidylinositol 4 kinase
TGN trans-Golgi network
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• Primary hemostasis.
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or BLOC1S6, a member of the BLOC-1 complex that 
promotes δ-granule formation.23,25 Downregulation of 
pallidin in RUNX1 haplodeficiency was suggested to 
underlie disrupted CD63 trafficking to δ-granules and 
impaired δ-granule biogenesis.23
NF-E2 has been described to regulate the expres-
sion of Rab27b, a small GTPase family that is strongly 
expressed in the megakaryocyte/ platelet lineage and 
colocalizes with both α- and δ-granules.26 NF-E2 KO 
megakaryocytes lack Rab27b expression, which has been 
shown to regulate the number of δ-granules per plate-
let.27 The closely related small GTPase Rab27a deficient 
in ashen (ash) mice, a model for Griscelli Syndrome has 
been implicated in dense granule release.26–28 Screening 
of a panel of patients with unexplained thrombocytopenia 
revealed defects in the gene encoding transcription factor 
FLI1.29 FLI1 is localized in the 11q24 arm on chromosome 
11q. This region is deleted in patients with Jacobsen and 
Paris-Trousseau syndrome (collectively called 11q dele-
tion syndromes), whose clinical symptoms include a.o. 
thrombocytopenia.30 In accordance with its proposed role 
in thrombopoiesis, Fli1−/− mice are embryonic lethal at day 
11.5 due to thrombocytopenia and abnormal vasculature 
development.29,30 Absence of FLI1 has previously been 
shown to induce macrothrombocytopenia, in addition 
to abnormal granule biogenesis that results in giant α-
granules and complete absence of δ-granules.31 Based 
on these findings, it was suggested that FLI1 may play 
a role in protein packaging in α-granules, whereas FLI1 
interactions with Hermansky-Pudlak syndrome (HPS) 
4 and RAB27B may regulate δ-granule biogenesis.19,31 
Dominant-negative mutations in the transcription factor 
GFI1B have been identified in patients with Gray platelet 
syndrome.32,33 Detailed morphological studies of patients 
with dominant-negative GFI1B mutation revealed lack of 
δ-granules as well as abnormalities in α-granule contents 
giving rise to a gray appearance in blood smears in a 
subset of platelets.34,35 The precise mechanisms under-
lying the observed changes in platelet LROs in patients 
with dominant-negative GFI1B mutations remain to be 
identified but are most likely caused by dysregulation of 
developmental programs involved in thrombopoiesis and 
markedly reduced expression of proteins that reside in 
α-granules.24 In summary, several transcription factors 
have been identified that affect the biogenesis of platelet 
LROs. Further elucidation of pathways controlling biogen-
esis of content delivery to platelet LROs is likely to shed 
light on general mechanisms that drive the formation of 
LRO compartments in other cell types, including melano-
cytes and endothelial cells (Figure 2).
Figure 1. Platelet and endothelial lysosome-related organelles.
A, Transmission electron micrographs of α- and δ-granules in platelets. α-granules are annotated with the respective letter and δ-granules with 
black arrowheads. Reprinted from Heijnen and van der Sluijs17 with permission. Copyright ©2015, International Society on Thrombosis and 
Haemostasis. The inset shows a detailed cryo electron micrograph of an α- and δ-granule (bar 50 nmol/L); this image was kindly provided by 
Dr H.F.G. Heijnen. B, Section of an electron cryotomogram of frozen-hydrated endothelial cells displaying Weibel-Palade bodies (WPBs), both 
containing intraluminal vesicles. B, I, WPB within a dense mesh of cytoskeletal filaments and surrounded by several cytoplasmic vesicles. B, ii, 
Section of an electron cryotomogram of a WPB with typical striations running parallel within the organelle. A cross-section of the WPB at the 
site of the red line is shown in the bottom right inset, which shows a highly organized stack of tubules that consist of condensed VWF (von 
Willebrand factor) multimers. Reprinted from Streetley et al8 with permission. Copyright ©2019, American Society of Hematology. ly indicates 
lysosomes.
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α-Granule Maturation: the Role of VPS33B/16B 
Complex and NBEAL2 in Cargo Trafficking and 
Retention
VPS33B is the first protein to be described as essen-
tial for α-granule maturation.36,37 VPS33B belongs to 
the family of S/M (Sec1/Munc18-like) proteins and 
has been proposed to promote assembly of newly form-
ing SNARE complexes by aligning SNARE helices from 
target and vesicle membranes.38 Mutations in VPS33B 
cause arthrogryposis-renal dysfunction-cholestasis syn-
drome, a multisystemic autosomal disorder that includes 
platelet deficiency.39 VPS33B deficiency results in the 
absence of α-granules and reduced levels of α-granule 
proteins like soluble cargo (Fbg and VWF) and membrane 
proteins (CD62P) that are presumably degraded in the 
lysosomes.36,37 Colocalization studies have shown that 
VPS33B is not associated with the Golgi, but it is mainly 
found on the recycling Rab11a positive endosomes, sug-
gesting that the VPS33B is part of the protein sorting 
machinery.36,37 Additionally, depletion of VPS33B in mega-
karyocytes not only results in α-granule deficiency but also 
multivesicular bodies (MVB) maturation.40 MVB has 2 dis-
tinct stages during maturation: type I and II.41 The former is 
characterized by abundant intraluminal vesicles, whereas 
the latter is identified by an electron-dense core and 
peripheral intraluminal vesicles.40,41 During megakaryo-
cyte development, MVB type I mature into type II, which 
are the progenitors of α-granules.41 Downregulation of 
VPS33B results in near absence of MVB type II along with 
α-granules, suggesting that VSP33B is primarily involved 
in MVB maturation and subsequent α-granule formation.40 
VPS33B is part of the heterohexameric tethering com-
plexes CORVET (class C core vacuole/endosome teth-
ering) and HOPS (homotypic fusion and vacuole protein 
sorting) that operate in endosome and lysosome fusion.42 
In addition, together with VPS16B, VPS33B forms the 
CHEVI (class C homologs in endosome-vesicle interac-
tion) complex which is recruited in a Rab11 dependent 
manner to recycling endosomes.43 Similar to VPS33B, 
genetic defects in the VPS16B encoding VIPAS39 gene 
are found in patients with the arthrogryposis-renal dys-
function-cholestasis syndrome.44 Loss of VPS16B results 
in reduction of VPS33B and α-granule proteins expres-
sion as well as defective α-granule formation similar to 
VPS33B KO.45 In a recent study, VPS33B and VSP16B 
are found to form a heterodimer smaller than CORVET 
and HOPS in megakaryocytes, which possibly does not 
include any other protein.36 The VPS33B/16B complex 
localizes on endosomes, which are closely related with the 
trans-Golgi network (TGN) and promotes protein traffick-
ing towards MVB before finally reaching α-granules.36
Another key component controlling α-granule forma-
tion is NBEAL2 (neurobeachin-like protein 2), a gene 
that encodes Neurobeachin-like 2 and is mutated in the 
storage pool disorder gray platelet syndrome.46 NBEAL2 
has been described to be involved in protein sorting in 
megakaryocytes.47 NBEAL2 KO megakaryocytes and 
platelets show greatly reduced intracellular levels of α-
granule components, such as Fbg and VWF, that are 
either sequestered by endocytosis or arrive in the α-
granule through biosynthetic pathways.47,48 Interestingly, 
Figure 2. Model for the initiation of the platelet plug during primary hemostasis.
A, Upon vascular damage, endothelial cells secrete their VWF (von Willebrand factor) content from their storage organelles the Weibel-Palade 
bodies (WPBs), which unfolds in long VWF strings. VWF strings form an adhesive platform for platelets to be arrested from circulation through 
the receptor/ ligand interaction of platelet GP1b-V-IX and VWF. B, Adhered platelets interact with exposed subendothelial collagen primarily 
through GPVI, which initiates an intracellular cascade leading to platelet activation. C, Activated platelets change their share and release 
their α- and δ-granules. ADP released from δ-granules binds to the P2Y12 receptor, which strongly potentiates collagen and thromboxane 
A2 (TXA2)–mediated platelet activation. Additionally, release of Fbg (fibrinogen) from α-granules contributes to platelet cross-linking through 
activation-dependent open conformation of integrin αIIbβ3 and platelet aggregation.
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when compared with VPS33B/16B mutations that result 
in platelets that lack both soluble cargo and membrane 
proteins like CD62P, NBEAL2−/− platelets, despite miss-
ing their soluble cargo, still contain a pool of releasable 
CD62P.37,45,48 Moreover, VPS33B and VPS16B expres-
sion is normal in NBEAL2 KO platelets, suggesting that 
NBEAL2 is involved at a later stage in α-granule matu-
ration, rather than promoting the formation of α-granule 
progenitors (MVB type II).48 Recently, Lo et al49 suggested 
that NBEAL2 is required for the retention of synthesized 
and endocytosed cargo through interaction with CD62P, 
potentially as a part of a multimolecular complex, to allow 
for packaging of cargo into maturing α-granules. In the 
absence of NBEAL2, α-granule cargoes, such as PF4, 
VWF, and Fbg, are not sufficiently retained, allowing for 
their transport to Rab11 positive recycling endosomes 
which are subsequently exocytosed.49 Further insights on 
the NBEAL2-dependent mechanisms can be provided 
by a recent proteomic study, which identified binding 
partners of NBEAL2 (Dock7, Sec16a, and Vac14) that 
may synergistically regulate α-granule formation.50
Therefore, the current view on α-granule maturation 
includes the heterodimeric CHEVI complex, composed 
of VPS33B and VSP16B, that promotes conversion of 
endosomes into α-granule progenitors, the MVB type II, 
and α-granules. After the α-granule cargo has arrived at 
its destination, NBEAL2 retains it intraluminally, thereby 
ensuring packaging of cargo into nascent and maturing 
α-granules (Figure 2).
δ-Granule Maturation: Proteins and Complexes 
Involved in a “Kiss-and-Run” Maturation
δ-granules, similarly to α-granules, go through a com-
plex maturation process that involves the delivery of spe-
cialized cargo catalyzed by several proteins and protein 
complexes. VPS33A has been identified as a crucial com-
ponent of multisubunit tethering complexes that control 
δ-granule formation.51 Vps33a−/− mice display a prolong 
bleeding time, which is attributed to decreased δ-granule 
ATP and serotonin secretion, due to their reduced num-
ber.51 Although this suggests that the VPS33 isoforms 
A and B may differentially traffic cargo towards δ- and 
α-granules respectively, mutations in VPS33A have not 
yet been reported.40,51
Intracellular vesicular trafficking is governed by Rab 
GTPases, which control specificity and directionality 
of the vesicles ensuring correct protein delivery to the 
final destination.52 In the case of δ-granule maturation, 
Rab32 and Rab38 play an important role by defin-
ing the delivery pathway from the endosomal compart-
ment to the maturing δ-granule.53 Both Rabs localize 
on Rab7a-positive MVBs, closely related to immature 
δ-granule, and are required for tethering and fusion of 
cargo-containing vesicles with the maturing δ-granule.53 
Double KO of Rab32 and Rab38, but not the single KO, 
results in morphological defects and decreased pres-
ence of δ-granules in mouse platelets, proving that they 
are both required for the biogenesis of δ-granules from 
the MVB compartment.54 Rab GTPases are considered 
to act as molecular switches, as they are found in an 
on GTP-bound and off GDP-bound state, each con-
trolled by GEFs (guanine nucleotide exchange factors) 
and GAPs (GTPase-activating proteins), respectively.52 
Rab32 and Rab38 are activated by BLOC-3, a multisub-
unit protein complex that promotes the correct localiza-
tion of Rab32/38 on its target membranes, which is an 
essential step in the formation and maturation of mela-
nosomes.55 Mutations in BLOC-3 subunits also lead to 
subtypes of the δ-storage pool disorder HPS (HPS1 and 
HPS4)53,56,57; however, to date, very little is known on how 
the BLOC-3 complex regulates formation and matura-
tion of δ-granules.
Similar to BLOC-3, AP (adaptor protein)-3 is another 
heteromeric protein trafficking complex, which promotes 
δ-granule formation by delivering proteins, like LAMP2 
(lysosome-associated membrane glycoprotein 2), the 
serotonin transporter VMAT2 (synaptic vesicular amine 
transporter), and most recently SLC53D3 (solute carrier 
family 35 member D3), to the forming granule.53,58 Muta-
tions in AP-3 subunits are associated with subtype HPS2 
(defect in AP3B1) and HPS10 (defect in AP3D1) δ-
storage pool disorders, which lead to complete absence 
or significantly lower numbers of δ-granules along with 
mislocalization or decreased expression of δ-granule 
cargo.58
Contrary to α-granule formation, δ-granules may 
follow a kiss-and-run maturation step, where luminal 
content in addition to membrane-bound proteins are 
exchanged between two maturing granules.59 TPC2 (two 
pore calcium channel protein 2) is a calcium release 
channel, which operates as a dual sensor for luminal pH 
and calcium.60 In megakaryocytes, TPC2 is part of the 
δ-granule limiting membrane and regulates the granule 
pH and calcium release, while it orchestrates the kiss-
and-run events, through which δ-granules can achieve 
homogenization and adjustment of their volume.59 Thus, 
TPC2 is a key regulator of a novel layer in δ-granule 
maturation.
Taken together, recent studies have shown that δ-
granule maturation is strongly tied to cargo delivery, 
regulated by Rab32 and Rab38 GTPases. BLOC-3 is a 
known GEF for both Rabs, and mutations in BLOC-3 
complex members result in HPS, therefore, by extension, 
it may regulate δ-granule formation. Similarly, VPS33A 
(vacuolar protein sorting-associated protein 33A) is 
shown to regulate δ-granule formation in mice; however, 
no current studies have been performed in human mega-
karyocytes, nor mutations have been described to have 
pathophysiological significance yet. Finally, δ-granules 
have an additional layer of a kiss-and-run mechanism 
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that normalizes their content and promotes their matura-
tion (Figure 2).
BIOGENESIS AND MATURATION OF WPB 
IN ENDOTHELIAL CELLS
VWF Maturation and ER-to-Golgi Protein 
Trafficking in the Biogenesis of WPBs
VWF, the main cargo of WPBs, undergoes an extensive 
and complex maturation process before finally being 
stored. VWF enters the early secretory pathway, as a sin-
gle prepro-polypeptide chain, and after the removal of the 
signal peptide, it is dimerized in the ER by the formation 
of disulfide bonds between the C-terminal CK (cysteine 
knot) domains of 2 pro-VWF monomers.61,62 At this stage, 
the ER acts as the quality control check point that allows 
only VWF dimers to proceed to exit and subsequent trans-
port to the Golgi apparatus.63,64 At the Golgi, VWF dimers 
are further processed: the propeptide is proteolytically 
cleaved, and VWF dimers are organized into head-to-
head multimers, before condensing into tubules and being 
packaged in TGN-associated WPBs.5,61 Blockage of any 
step during VWF maturation may lead to abnormal forma-
tion of WPBs, like in the case of von Willebrand disease 
(VWD) where mutations in the VWF gene affect the WPB 
formation.65 Interestingly, mutations have been reported 
in the D3, and C2 domains of VWF (p.Cys1130Phe and 
p.Cys2671Tyr, respectively) that affect ER exit of VWF 
dimers and lead to VWF retention in the ER as well as 
the rarer occurrence of WPBs.64 Similar results with ER 
retention of VWF and formation of abnormal WPBs have 
been recently shown in Sec22b knockdown endothelial 
cells.66 Sec22b is a SNARE protein that regulates the 
fusion of COPII (coat protein complex II)-coated ER-exit-
ing vesicles.67 Downregulation of Sec22b affects the rate 
of ER/Golgi transport of VWF and other proteins, which 
consequently affects the Golgi morphology and results in 
the formation of short and stubby WPBs, probably due to 
Golgi fragmentation.66,68 Additionally, we and others have 
shown that Sec22b is paired with STX5 (syntaxin-5) as 
part of the ER-Golgi SNARE machinery, and depletion 
of STX5 in endothelial cells strongly affects WPB forma-
tion.69,70 Depletion of STX5 in endothelial cells leads to 
decreased intracellular VWF storage levels and extensive 
Golgi dispersal, which results in the formation of shorter 
and rounder WPBs.69 It has previously been shown that 
AP1/clathrin coats control WPB biogenesis at the level 
of the TGN.71 The small GTPase Arf1 (ADP-ribosylation 
factor 1) is crucial for targeting the AP-1 complex to 
the TGN, and recently, GBF1 (Golgi-specific brefeldinA-
resistance guanine nucleotide exchnage factor 1) a gua-
nine exchange factor for members of the Arf family has 
been implicated in WPB biogenesis.72 Intriguingly, deple-
tion of GBF1 resulted in accumulation of unprocessed 
VWF in the ER, whereas very long, often bent WPBs were 
observed in close proximity to the TGN. The metabolic 
regulator 5′ AMPK (AMP-activated kinase) has been 
shown to modulate the activity of GBF1 suggesting that 
environmental cues can regulate number and WPB size 
through their effect on ER-to-Golgi.72 Taken together, 
these exciting findings indicate that modulation of ER-to-
Golgi trafficking of VWF can significantly alter the WPB 
formation by retaining VWF in the ER and thus decrease 
the amount of mature VWF that can be stored in WPBs 
while governing morphology of WPB emerging from the 
TGN (Figure 3).
TGN Emerging WPBs: Monitoring the 
Morphology of Immature WPBs
WPBs biogenesis is taking place at the TGN, where VWF 
units, known as VWF quanta, are tightly co-packaged 
in the form of tubular segments in newly synthesized 
WPB.68 The first factor the regulates WPBs at the TGN 
site is the actual morphology of the Golgi. Dispersed 
Golgi and TGN morphology can negatively affect the abil-
ity of endothelial cells to incorporate sufficient amount 
of VWF quanta in the newly synthesized WPBs, limiting 
their length and affecting their string formation on the 
endothelial apical side.66,68,69,73 The second factor that 
promotes WPB biogenesis is the VWF tubulation state. 
Endothelial cells that lack HPS6, a subunit of BLOC-2 
complex associated with HPS type 6, have abnormal 
VWF tubulation and misshaped WPBs, potentially due 
to failed recruitment of proteins involved in acidification 
of WPB milieu.74 Although the Golgi/TGN morphology 
sets the bar for WPB size and VWF tubulation affects 
the formation itself, more proteins at the site regulate 
WPB biogenesis like the AP-1 complex.71 AP-1/clathrin 
is speculated to act as a corset, stabilizing the forming 
WPB during VWF-tubule assembly and preventing pre-
mature budding.71 In parallel, Dlg1 (discs large 1) protein, 
associates with both mature VWF and AP-1 complex 
on the TGN, suggesting that Dlg1 may link VWF with 
a yet-unidentified transmembrane partner to the AP-1 
complex.75 Both AP-1 and Dlg1 knockdowns result in 
ablation of elongated WPBs and restrictive localization 
of VWF to perinuclear puncta.71,75 AP-1 complex target-
ing and docking on the TGN is dependent on phospha-
tidylinositol 4 phosphate–rich domains, whose levels are 
determined by Golgi resident PI4K (phosphatidylinositol 
4 kinases).76 In endothelial cells, PI4KII-depletion disturbs 
the WPB intraorganellar environment due to abnormal 
VWF folding.77 The resulting WPBs are shorter, suggest-
ing a critical role for PI4KIIs in WPB biogenesis, as it 
could recruit AP-1 at the TGN.77 At early stages of WPB 
biogenesis, WPBs do not leave the Golgi apparatus fast, 
but rather maintain multiple connections with it, for cargo 
delivery.78 More nontubulated VWF is added to the newly 
formed WPB together with other proteins until the for-
mation is completed and the clathrin coat is removed.78 In 
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summary, WPB is formed at the TGN, which regulates its 
size. Their biogenesis is dependent on the recruitment of 
AP-1 complex at the PI4P-riched TGN domains, where, 
in conjunction with Dlg1 and clathrin, they create a girdle 
around the forming WPB. The WPB remains attached 
to the Golgi apparatus for the further delivery of protein 
cargo (Figure 3).
WPB Maturation: Acquisition of More Protein 
Cargo
Similar to α- and δ-granules, WPBs mature through 
the receipt of transmembrane cargo. WPBs, apart 
from soluble cargo like VWF, also contain proteins 
like CD62P and CD63, that follow different pathways 
arriving to the mature WPB. It has been shown that 
CD62P is accumulated on the budding WPB at the 
TGN through its cytoplasmic tail motif, probably while 
the forming WPB maintains multiple connections with 
the TGN as described above.78,79 In contrast, CD63 is 
trafficked to the WPB at a later stage during matura-
tion, following and AP-3 dependent route.79 Mutations 
that affect the AP-3 complex formation lead to abnor-
mal WPB maturation, resulting in aberrant trafficking 
of CD63 as well as SNARE proteins like VAMP8 (ves-
icle-associated membrane protein 8) to other cellular 
compartments.79,80 Improper WPB formation results in 
reduced hormone-evoked VWF secretion, indicating 
Figure 3. Model for lysosome-related organelles (LRO) formation in megakaryocytes: α- and δ-granule.
In megakaryocyte (MKs), transcription factors which regulate the expression of several genes that encode proteins, which are involved in the 
biogenesis of LROs. In the case of α-granules, the first identified step of their biogenesis is the Rab1b-dependent endoplasmic reticulum 
(ER)-to-Golgi protein trafficking. After newly synthesized proteins have been fully processing in the Golgi, they are sorted in Rab5a recycling 
endosomes, which serve as distribution center for new and recycled proteins. Endocytosed cargo, such as fibrinogen, is also targeted to early 
endosomes. The VPS33B/16B complex facilitates the transport of proteins to Rab7a positive multivesicular body (MVB) II, the progenitors of 
α-granules. Cargo retention in the maturing α-granule and prevention of premature release of content is achieved by NBEAL2 (neurobeachin-
like protein 2) most likely by virtue of its binding to the cytoplasmic tail of CD62P, thereby providing a content-stabilizing coat for α granules. 
In the absence of NBEAL2 α-granular content is released through Rab11a positive recycling endosomes. On the other hand, δ-granule 
progenitors are Rab7a MVBI, that supply the maturing granule with appropriate cargo. Several proteins and protein complexes have been 
suggested to promote δ-granule maturation, including the well-characterized AP (adaptor protein)-3 complex, BLOC-1, and BLOC-3 and the 
small GTPases Rab27a/b and Rab32/38, while VPS33A has been implicated in δ granule biogenesis in mice. Additionally, δ-granules have an 
extra step during maturation, known as kiss-and-run, though which they can exchange content and achieve homogenization while adjusting their 
volume. Fbg indicates fibrinogen; HPS, Hermansky-Pudlak syndrome; and VWF, von Willebrand factor.
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that WPB maturation is required for production of 
organelles with proper exocytotic behavior.80 Similar to 
platelet LROs, WPBs acquire Rab proteins during the 
maturation process, like Rab3B and 3-dimensional and 
Rab27a that have been shown to regulate their exo-
cytotic behavior.81 It has been suggested that Rab27a 
is maturation marker that arrives at the WPB at a later 
stage, separating the WPBs into 2 populations: the 
immature Rab27a negative and the mature Rab27a 
positive82 (Figure 3). The recruitment of Rab27a on the 
WPB membrane is potentially controlled by changes 
on the lipid/protein local environment driven by VWF.82 
Interestingly, although a new study sheds light on the 
interacting partners of mature WPB Rabs (Rab3b, 
Rab3d, and Rab27a), it also identifies proteins that 
are involved in WPB biogenesis and VWF ER-to-Golgi 
trafficking, like the aforementioned Sec22b, STX5, and 
GBF1, suggesting that our knowledge on WPB forma-
tion is still incomplete.83
DISORDERS ASSOCIATED WITH 
ABNORMAL α-, δ-GRANULE, AND WPB 
FORMATION
Several disorders have been described to negatively 
affect the biogenesis of megakaryocyte/ platelet gran-
ules and endothelial cell WPBs (Table). Gray platelet 
syndrome is a disease that affects the α-granule for-
mation, caused by mutations in the NBEAL2 gene, and 
clinically is characterized by macrothrombocytopenia 
and decreased platelet activity.84 Similar to Gray plate-
let syndrome, Quebec platelet syndrome is an α-storage 
pool disorder that is caused by mutation in PLAU 
(urokinase-type plasminogen activator), resulting in 
proteolysis of α-granule proteins, reducing their expres-
sion.86 Another disorder that is presented with bleeding 
tendency, in addition to liver, skin, and central nervous 
system complications, is arthrogryposis, renal dysfunc-
tion, and cholestasis syndrome. Arthrogryposis-renal 
Table. Table of Genetic Disorders Affecting Hemostatic LRO Formation
LRO Disorder Abbreviation Subtype Mutated Gene Bleeding Phenotype Reference
α-granule Gray platelet syndrome GPS … NBEAL2 Moderate-severe Gunay-Aygun et al,46 
Albers et al,84 Kahr 
et al85
Quebec platelet syndrome QPS … PLAU Moderate-severe Hayward et al86
Arthrogryposis, renal dysfunction, 
and cholestasis syndrome
ARCS ARCS1 VPS33B Severe Cullinane et al,44 Zhou 
and Zhang87
ARCS2 VPS16B (VIPAS39)
δ-granule Hermansky-Pudlak syndrome HPS HPS1 HPS1 Mild-severe Wei et al88
HPS2 AP3B1 Karampini et al,80 Wei et 
al,88 Meng et al89
HPS3 HPS3 Wei et al88
HPS4 HPS4 Wei et al,88 Meng et al89
HPS5 HPS5 Wei et al88
HPS6 HPS6 Ma et al,74 Wei et al,88 
Sharda et al90
HPS7 DTNBP1 Wei et al88
HPS8 BLOC1S3 Wei et al88
HPS9 PLDN Wei et al,88 Meng et al89
HPS10 AP3D1 Ammann et al91
Chediak-Higashi syndrome CHS … LYST Mild-moderate Sharma et al92
Griscelli syndrome GS GS1 MYO5A Not reported Van Gele et al93
GS2 RAB27A Van Gele et al93
GS3 MLPH Van Gele et al93
Weibel-Pal-
ade body
Von Willebrand disease VWD VWD1 VWF Varies according to 
VWF levels
Leebeek et al94
other genes
VWD2 VWF Mild-moderate Leebeek et al,94 Nurden et 
al,95 Nurden et al96
VWD3 VWF Severe Leebeek et al,94 Nurden 
et al97
Genetic disorders and their respective mutated genes that lead to a bleeding phenotype. Most of the disorders are categorized as rare, with the exception of VWD, 
the most common bleeding disorder, with prevalence of up to 1% of the general population. ARCS, arthrogryposis-renal dysfunction-cholestasis; CHS, Chediak-Higashi 
syndrome; GPS, gray platelet syndrome; GS, Griscelli syndrome; HPS, Hermansky-Pudlak syndrome; LRO, lysosome-related organelles; LYST, lysosomal-trafficking 
regulator; NBEAL2, neurobeachin-like protein 2; PLAU, urokinase-type plasminogen activator; QPS, Quebec platelet syndrome; and VWD, von Willebrand disease.
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dysfunction-cholestasis syndrome consists of 2 types 
that influence the expression of VPS33B and VPS16B, 
the subunits of CHEVI complex, which is responsible 
for α-granule maturation.87 Likewise, HPS is a multi-
systemic disorder with 10 identified genetic types that 
affect skin pigmentation, hemostasis, and lung tissue 
consistency, along with reported immunodeficiency in 
some types.88,91 The mutated genes that cause HPS 
encode proteins that primarily facilitate δ-granule bio-
genesis and maturation; thus, in most cases, δ-granules 
are absent from the circulating platelets. Diseases that 
are characterized by δ-storage pool deficiency, along 
with hypopigmentation, are Chediak-Higashi and Gris-
celli syndrome (type 2). Chediak-Higashi is caused by 
mutations in the LYST (lysosomal-trafficking regulator) 
gene, which results in decreased δ-granule components 
and dysfunctional platelets, whereas Griscelli syndrome 
2 is caused by mutations in RAB27A, which supports 
the retention of δ-granule cargo, but the effects are 
dependent on the genetic background.28,92,93 Interest-
ingly, although LYST exhibits great similarity to NBEAL2 
in terms of protein structure—as they both contain 
BEACH (beige and Chediak-Higashi), ARM (Armadillo) 
and WD40 domains—they participate in different steps 
during granule formation: the former affecting δ- and 
the latter affecting α-granule maturation.85,98 This indi-
cates the great complexity of the pathways involved in 
the biogenesis of LROs. Finally, WPB biogenesis and 
maturation is affected in the most common bleeding 
disorder, known as VWD. VWD is characterized by quan-
titative or qualitative defects in VWF, the main cargo of 
WPBs. VWD is subcategorized into 3 types, depending 
on the mutations and how they alter VWF synthesis and 
Figure 4. Model for Weibel-Palade bodies (WPB) formation in endothelial cells.
Several transcription factors have been found to positively regulate VWF (von Willebrand factor) expression, the driving force of WPB 
biogenesis. VWF exits endoplasmic reticulum (ER) to arrive at the Golgi in a GBF1-dependent manner. The fusion of ER-exiting vesicles 
is dependent on the interaction of Sec22b with the cognate SNARE on the Golgi, STX5. After VWF is fully processed and multimerized, it 
condenses in tubules and packages in VWF quanta in the emerging granule. At this stage, AP (adaptor protein)-1 localizes the trans-Golgi 
network (TGN), by means of PI4P-riched rich domains, and acts like a corset for forming WPBs, preventing it from premature budding off. The 
newly synthesized WPB maintains several connections to the TGN, for the further transfer of proteins potentially like CD62P. The immature 
WPB undergoes a maturation process, where is acquires more proteins from the endosomal compartment in an AP-3 dependent manner. 
Mature WPBs are positive for the small GTPases, RAB27A, 3B, and 3D as well as Slp4-a and migrate towards the periphery of the cell, ready 
to be secreted upon demand.
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maturation, which, in turn, can influence the biogenesis 
and the morphology of WPBs.65,94
Either derived from MVBs or directly formed at the 
TGN, LRO biogenesis and maturation are governed by 
universal pathways.99 Hence, there are multisystemic dis-
orders that can alter the biogenesis of >1 LRO. Such a 
case is that HPS, apart from defective δ-granule forma-
tion, has been shown to alter α-granule protein release 
(HPS2, HPS4, and HPS9), whereas, it has also been 
described to influence WPB morphology and maturation 
(HPS2 and HPS6).74,80,89,90 Additionally, VWD, especially 
type 2 and 3, has been associated with impaired mega-
karyopoiesis and platelet dysfunction, implicating VWF/
GPIb-V-IX interactions in a novel role during platelet 
production.95–97
Taken together, LRO disorders comprise a heteroge-
neous group that has a multisystemic phenotype. In most 
cases, the bleeding tendency caused by these disorders 
has been attributed to a particular LRO; however, as we 
understand that cellular mechanisms are shared between 
cell types, it becomes clearer that >1 LRO can be affected.
PERSPECTIVE
Although we have a better grasp on some aspects, 
we still need to cover a lot of ground to fathom out 
the tightly regulated cellular mechanisms involved in 
the hemostatic LRO formation. What is seemingly the 
most important factor in LRO biogenesis and matu-
ration is the correct delivery of specialized cargo. It 
has recently been appreciated that ER-to-Golgi pro-
tein influx is the first regulatory step in LRO formation, 
through which the cell can control the protein supply 
to progenitor compartments in response to environ-
mental cues like glucose levels. However, the exact 
molecular mechanisms and protein complexes are 
poorly defined. Additionally, it has been described that 
the same type of granules can contain different pack-
aged proteins, giving rise to subpopulations that that 
may undergo different modes of exocytosis.100 How is 
cargo distributed differently? Are the same proteins 
monitoring different components’ trafficking, and if so, 
what are the molecular cues for differential composi-
tion? These are questions that we cannot yet answer, 
which points out the need for further examination. As 
far the LRO cargo is concerned, recently, it has been 
shown that LROs contain also CD63 positive intralu-
menal vesicles that contribute to intercellular commu-
nication and modulate the targeted cells through acute 
secretion upon stimulation.8,101 However, whether the 
process of intraluminal vesicle accumulation in LROs 
is intentional or unintentional and how the cell may 
control this acquisition are still unknown.
It is now understood that, despite the different char-
acteristics of LROs types, several pathways can have 
a universal impact in the formation of >1 granule type. 
Therefore, disease models that are traditionally con-
nected with one particular LRO can be used to study the 
formation of another LRO in a different cell type. In such 
cases, the recent developments in induced pluripotent 
stem cells can be utilized in LRO biology. Starting from 
fibroblasts, CD34-positive progenitor cells and blood 
outgrowth endothelial cells, cells from various disease 
models can easily be reprogrammed in a pluripotent 
state and differentiate into different cell types, containing 
different LROs. In this way, the parallel monitoring of the 
mechanisms involved in granule formation can highlight 
the similarities or point out the differences.
Megakaryocyte/platelet and endothelial LROs are 
the major players in primary hemostasis, regulating 
cell-cell communication and secreting bulk amounts of 
hemostatic proteins. Mutation in genes that govern their 
formation results in abnormal morphology, secretion, 
and finally, in bleeding disorders. Therefore, improved 
comprehension of their biogenesis and cargo retention 
can lead to better and more personalized treatments for 
patients with bleeding disorders as well as patients with 
thrombo-inflammatory and other vascular disorders.
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